U.S., March 10 -- ClinicalTrials.gov registry received information related to the study (NCT07457164) titled 'A Phase 2 Study Investigating the Pharmacokinetics, Pharmacodynamics, Efficacy and Safety of Teverelix DP, a Gonadotropin-releasing Hormone (GnRH) Antagonist, in Patients With Advanced Prostate Cancer' on Feb. 24.
Brief Summary: The purpose of this clinical trial is to test the effectiveness of a dosing regimen of Teverelix DP castration rate defined as the cumulative probability of testosterone suppression to 90% to meet the evaluation criteria for efficacy.
The main question it aims to answer is:
*Is the dosing regimen of Teverelix DP in this study effective at achieving the required testosterone suppression to castrate levels...